Heghine Khachatryan: Addressing Critical Gaps in Cancer-Associated VTE
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, reposted from RPTH Journal on LinkedIn, adding:
”Cancer-associated VTE: an old problem, still unresolved
Despite decades of research, cancer-associated venous thromboembolism (VTE) remains a major cause of morbidity and mortality.
This timely editorial in Research and Practice in Thrombosis and Haemostasis highlights critical gaps—from real-time epidemiologic data to optimal thromboprophylaxis and bleeding risk stratification—and points toward future, cancer-specific solutions.
A strong reminder that prevention, individualized risk assessment, and innovation in anticoagulation must remain a global priority in oncology and hematology.
Editorial by Alok Khorana
Research and Practice in Thrombosis and Haemostasis”
Quoting RPTH Journal‘s post:
”Cancer-associated VTE: an old problem, still unresolved
RPTH Journal Editorial by Alok Khorana
As highlighted by Maiocco et al. in RPTH Journal, it remains puzzling that VTE, a complication of cancer known since the 19th century, continues to heavily burden modern oncology care.
- Cancer patients face a 9- to 20-fold higher risk of VTE, even with contemporary therapies
- In a nationwide US inpatient analysis, 8.1% of cancer-related hospitalizations were complicated by VTE
- VTE remains strongly associated with higher mortality, longer hospital stays, and higher costs
- Despite decades of awareness, robust evidence for inpatient thromboprophylaxis in cancer patients is still lacking
Read the editorial here
Read the study by Giuseppe Maiocco et al here”
Title: The public health impact of cancer-associated venous thromboembolism: looking to the future
Authors: Alok Khorana
Read the Full Editorial on RPTH Journal

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series